Keros Therapeutics (KROS) Cash & Equivalents (2019 - 2026)
Keros Therapeutics' Cash & Equivalents was $257.61 million in Q2 2026, down 62.7% from $690.22 million a year earlier.
Powered by 
Analysis
Keros Therapeutics (KROS) Cash & Equivalents (2019 - 2026) Analysis & Trends
At the end of FY2025, Cash & Equivalents at Keros Therapeutics came in at $287.42 million, down 48.7% from FY2024.
- Cash & Equivalents shows a five-year compound annual growth rate of 1.6% (FY2020 to FY2025).
- In earlier years, Cash & Equivalents was $559.93 million in FY2024 (+69.1%), $331.15 million in FY2023 (+18.7%), $279.05 million in FY2022 (+21.3%) and $230.04 million in FY2021 (-13.5%).
- The Q2 2026 figure marks the lowest quarterly Cash & Equivalents since Q3 2022.
- Compared with a year earlier, Cash & Equivalents was higher in five of the last seven quarters, with growth averaging 29.4%.
- The best year-over-year quarter for Cash & Equivalents over five years was Q3 2024 (growth of 84.3%); the worst was Q2 2026 (a decline of 62.7%).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,137.66 Bn | 1,106.24 Bn | 19.71 Bn | 8.95 Bn |
| 2 | Johnson & Johnson | 636.13 Bn | 556.00 Bn | 17.30 Bn | 16.91 Bn |
| 3 | AbbVie | 505.28 Bn | 478.39 Bn | 12.70 Bn | 6.57 Bn |
| 4 | Merck | 358.10 Bn | 312.48 Bn | 12.21 Bn | 6.85 Bn |
| 5 | Novartis Ag | 292.59 Bn | 256.58 Bn | 11.24 Bn | 7.62 Bn |
| 6 | Astrazeneca | 265.81 Bn | 239.50 Bn | 12.86 Bn | 4.90 Bn |
| 7 | Amgen | 237.53 Bn | 192.93 Bn | 7.24 Bn | 13.99 Bn |
| 8 | Gilead Sciences | 194.67 Bn | 168.86 Bn | 6.22 Bn | 3.18 Bn |
| 9 | Pfizer | 171.17 Bn | 117.82 Bn | 10.94 Bn | 976.00 Mn |
| 10 | Keros Therapeutics | 222.95 Mn | -1.71 Bn | - | 257.61 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 257.61 Mn |
| Dec 31, 2025 | 287.42 Mn |
| Sep 30, 2025 | 693.47 Mn |
| Jun 30, 2025 | 690.22 Mn |
| Mar 31, 2025 | 720.54 Mn |
| Dec 31, 2024 | 559.93 Mn |
| Sep 30, 2024 | 530.68 Mn |
| Jun 30, 2024 | 405.86 Mn |
| Mar 31, 2024 | 442.44 Mn |
| Dec 31, 2023 | 331.15 Mn |
| Sep 30, 2023 | 287.89 Mn |
| Jun 30, 2023 | 322.03 Mn |
| Mar 31, 2023 | 351.43 Mn |
| Dec 31, 2022 | 279.05 Mn |
| Sep 30, 2022 | 239.43 Mn |
| Jun 30, 2022 | 215.62 Mn |
| Mar 31, 2022 | 228.59 Mn |
| Dec 31, 2021 | 230.04 Mn |
| Sep 30, 2021 | 221.35 Mn |
| Jun 30, 2021 | 237.11 Mn |
API Access
Keros Therapeutics Cash & Equivalents API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=cash-and-equivalents&ticker=KROS&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "cash-and-equivalents", "ticker": "KROS", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=cash-and-equivalents&ticker=KROS&period=max&api_key=YOUR_API_KEY");
const data = await res.json();